45 Atopic Dermatitis Clinical Trials in La Jolla, CA (2026)

Q: How do I join a clinical trial in La Jolla?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you.

Recruiting Atopic Dermatitis Studies in La Jolla

NCT04194138Recruiting

Complex Adult Deformity Surgery (CADS)

Evaluate surgical treatment outcomes and identify best practice guidelines for complex adult spinal deformity (ASD) patients, including radiographic and clinical outcomes, surgical and postoperative c...

La Jolla, CA1,500 participantsInternational Spine Study Group Foundation

View Study Details

NCT05938478Recruiting

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

The goal of this observational study is to learn about exposure to tralokinumab during pregnancy, as well as atopic dermatitis (AD) during pregnancy. The main question the study aims to answer is whe...

La Jolla, CA900 participantsUniversity of California, San Diego

View Study Details

NCT06525220Recruiting

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head an...

La Jolla, CAPHASE3700 participantsMerus N.V.

View Study Details

NCT05417594Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participan...

La Jolla, CAPHASE1695 participantsAstraZeneca

View Study Details

NCT06112314Recruiting

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanc...

La Jolla, CAPHASE3680 participantsImmunocore Ltd

View Study Details

NCT06788990Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficeraf...

La Jolla, CAPHASE2650 participantsBicara Therapeutics

View Study Details

NCT07129993Recruiting

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progre...

La Jolla, CAPHASE2630 participantsDaiichi Sankyo

View Study Details

NCT06496178Recruiting

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incur...

La Jolla, CAPHASE3600 participantsMerus N.V.

View Study Details

NCT06581432Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of th...

La Jolla, CAPHASE2588 participantsBoehringer Ingelheim

View Study Details

NCT03526835Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC...

La Jolla, CAPHASE1560 participantsMerus N.V.

View Study Details

NCT03093116Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotre...

La Jolla, CAPHASE1500 participantsTurning Point Therapeutics, Inc.

View Study Details

NCT04892173Recruiting

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab ...

La Jolla, CAPHASE3500 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT06311214Recruiting

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfor...

La Jolla, CAPHASE2500 participantsNational Cancer Institute (NCI)

View Study Details

NCT07276399Recruiting

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or ...

La Jolla, CAPHASE3500 participantsJanssen Research & Development, LLC

View Study Details

NCT06384807Recruiting

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors....

La Jolla, CAPHASE1500 participantsBiohaven Therapeutics Ltd.

View Study Details

NCT05007782Recruiting

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS...

La Jolla, CAPHASE1416 participantsGilead Sciences

View Study Details

NCT06662500Recruiting

FORWARD CAD IDE Study

The FORWARD CAD IDE Study is a Prospective, Multicenter, Single-Arm, Investigational Device Exemption (IDE) Study conducted to assess the safety and effectiveness of the Shockwave Intravascular Lithot...

La Jolla, CANA408 participantsShockwave Medical, Inc.

View Study Details

NCT06264180Recruiting

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage III...

La Jolla, CAPHASE3400 participantsReplimune Inc.

View Study Details

NCT06241456Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in pa...

La Jolla, CAPHASE1351 participantsFate Therapeutics

View Study Details

NCT04752722Recruiting

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phase...

La Jolla, CAPHASE1350 participantsenGene, Inc.

View Study Details

NCT05434234Recruiting

A Study of YL201 in Patients With Advanced Solid Tumors

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) follo...

La Jolla, CAPHASE1312 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT04585750Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tum...

La Jolla, CAPHASE1300 participantsPMV Pharmaceuticals, Inc

View Study Details

NCT04429542Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergis...

La Jolla, CAPHASE1292 participantsBicara Therapeutics

View Study Details

NCT06385080Recruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in...

La Jolla, CAPHASE1287 participantsJanssen Research & Development, LLC

View Study Details

NCT06638307Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer....

La Jolla, CAPHASE1240 participantsStemline Therapeutics, Inc.

View Study Details

NCT06997029Recruiting

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer....

La Jolla, CAPHASE1234 participantsBristol-Myers Squibb

View Study Details

NCT04888104Recruiting

Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients

Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients...

La Jolla, CA225 participantsInternational Spine Study Group Foundation

View Study Details

NCT04671667Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with...

La Jolla, CAPHASE2188 participantsNational Cancer Institute (NCI)

View Study Details

NCT06600321Recruiting

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended d...

La Jolla, CAPHASE1158 participantsAlnylam Pharmaceuticals

View Study Details

NCT06603844Recruiting

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and hav...

La Jolla, CAPHASE1156 participantsCorbus Pharmaceuticals Inc.

View Study Details

NCT07124117Recruiting

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and putative recommended phase 2 dose of OBI-902 (study drug) as monotherapy. Part B (Cohort ...

La Jolla, CAPHASE1147 participantsOBI Pharma, Inc

View Study Details

NCT05873686Recruiting

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected...

La Jolla, CAPHASE1140 participantsNuvectis Pharma, Inc.

View Study Details

NCT03480971Recruiting

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week t...

La Jolla, CAPHASE2120 participantsMatrix Biomed, Inc.

View Study Details

NCT06532279Recruiting

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiat...

La Jolla, CAPHASE298 participantsNRG Oncology

View Study Details

NCT06801236Recruiting

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC)....

La Jolla, CAPHASE188 participantsAcerand Therapeutics (Hong Kong) Limited

View Study Details

NCT05327010Recruiting

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

This phase II trial tests whether ZEN003694 (ZEN-3694) in combination with talazoparib works to shrink tumors in patients with solid tumors that are unlikely to be cured or controlled with treatment a...

La Jolla, CAPHASE288 participantsNational Cancer Institute (NCI)

View Study Details

NCT03739814Recruiting

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly ...

La Jolla, CAPHASE284 participantsNational Cancer Institute (NCI)

View Study Details

NCT04282044Recruiting

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination w...

La Jolla, CAPHASE160 participantsBioEclipse Therapeutics

View Study Details

NCT06824974Recruiting

Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer

This is a feasibility study that will collect data to assess the potential effect of nutritional intervention. This prospective single-site trial will enroll adult patients with liver diseases such as...

La Jolla, CANA50 participantsUniversity of California, San Diego

View Study Details

NCT06900595Recruiting

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and...

La Jolla, CAPHASE248 participantsNational Cancer Institute (NCI)

View Study Details

NCT07219212Recruiting

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemo...

La Jolla, CAPHASE145 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT06790602Recruiting

Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

This is a Phase 2 trial evaluating the combination of cemiplimab with the standard of care chemotherapy agent gemcitabine for the treatment of patients with metastatic pancreatic ductal adenocarcinoma...

La Jolla, CAPHASE243 participantsUniversity of California, San Diego

View Study Details

NCT06798012Recruiting

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over...

La Jolla, CAPHASE236 participantsTakeda

View Study Details

NCT06639724Recruiting

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chem...

La Jolla, CAPHASE136 participantsUniversity of California, San Diego

View Study Details

NCT06860594Recruiting

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a peri...

La Jolla, CAPHASE130 participantsNational Cancer Institute (NCI)

View Study Details

About Atopic Dermatitis Clinical Trials in La Jolla

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 45 atopic dermatitis clinical trials recruiting participants in La Jolla, CA. These studies are seeking a combined 15,433 participants. Research is being sponsored by International Spine Study Group Foundation, University of California, San Diego, Merus N.V. and 28 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in La Jolla — FAQ

Are there atopic dermatitis clinical trials in La Jolla?

Yes, there are 45 atopic dermatitis clinical trials currently recruiting in La Jolla, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in La Jolla?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the La Jolla research site will contact you about next steps.

Are clinical trials in La Jolla free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many La Jolla studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 45 active trials in La Jolla are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated August 31, 2026 from ClinicalTrials.gov